BASEL,
Switzerland, Jan. 25
/PRNewswire/ - Neuro-Biotech Corp. (MRES-OTSQB) is pleased to
announce the signing of a Letter of Intent with a major distributor
in Israel. Both groups are
discussing the details of a Licensing Agreement based on similar
terms and conditions as the recently negotiated agreement with the
Russian company Credo-TM.
Furthermore, Neuro-Biotech intends to contract
the manufacturing of the tests ordered by its Licensee in
Israel and to that effect
discussions have already taken place with Sigma-Aldrich a renowned
pharmaceutical firm in Israel.
With the signing of this Letter of Intent with
the Israelis, Neuro-Biotech gains a strong foothold and is able to
pursue in an accelerated way the implementation of its Licensee
network throughout the world. This allows the Company to initiate
the next phase of its development plan namely the creation of its
own "Technological Showcase" to support the training of technicians
and the development of new products.
For more information on Neuro-Biotech Corp or to
contact a company representative, please visit:
www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Act of 1995.
Certain statements in this press release may contain words such as
"anticipates," "believes," "could," "expects," "intends," "may,"
"projects," "targets" and other similar language that is considered
forward-looking statements. These forward-looking statements are
subject to certain risks and uncertainties and persons reading this
release are cautioned that such statements are only predictions,
and that the Company's actual future results or performance may be
materially different. The Company disclaims any intention or
obligation to update or revise forward-looking information, whether
as a result of new information, future events, or otherwise, could
cause the company's actual results to differ materially from those
indicated in any forward-looking statements.
CONTACT
Neuro-Biotech Corp.
Dr. Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com
SOURCE Neuro-Biotech Corp.
Copyright . 25 PR Newswire